Pipeline Review for Asthma - H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Asthma - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 13, 46, 31, 6, 119, 29 and 9 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 29 and 8 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Asthma - Overview
  • Asthma - Therapeutics Development
  • Asthma - Therapeutics Assessment
  • Asthma - Companies Involved in Therapeutics Development
  • Asthma - Drug Profiles
  • Asthma - Dormant Projects
  • Asthma - Discontinued Products
  • Asthma - Product Development Milestones
  • Appendix

Companies Mentioned

  • 2A Pharma AB
  • 3SBio Inc
  • 4D Pharma Plc
  • AB Science SA
  • AbbVie Inc
  • Abeome Corp
  • Adamis Pharmaceuticals Corp
  • Adare Pharmaceuticals Inc
  • Advagene Biopharma Co Ltd
  • Aerami Therapeutics
  • Akeso Biopharma Inc
  • Algomedix Inc
  • ALK-Abello AS
  • Allergan Plc
  • Amgen Inc
  • Amphastar Pharmaceuticals Inc
  • AnGes Inc
  • Antisense Therapeutics Ltd
  • Apollo Endosurgery Inc
  • Apollo Therapeutics LLC
  • Aquilon Pharmaceuticals SA
  • Argenx SE
  • Artax Biopharma Inc
  • Artizan Biosciences Inc
  • ASIT Biotech SA
  • Aslan Pharmaceuticals Ltd
  • AstraZeneca Plc
  • Atrapos Therapeutics LLC
  • Aurigene Discovery Technologies Ltd
  • AusBio Ltd
  • Avidin Ltd
  • Bai Shuo Beijing Pharmaceutical Technology Co Ltd
  • Bilix Co Ltd
  • Biocon Ltd
  • BiOraliX BV
  • BiosanaPharma BV
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc
  • Celon Pharma SA
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Chiesi Farmaceutici SpA
  • Chronic Airway Therapeutics Ltd
  • ConMed Biosciences Inc
  • Crossject SA
  • CrystalGenomics Inc
  • CSL Ltd
  • CSPC Pharmaceutical Group Ltd
  • Cumberland Pharmaceuticals Inc
  • Any Many More Companies!

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sj61h0


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900